Phenotyping-genotyping of alternatively spliced genes in one step:: study of CYP3A5*3 polymorphism

被引:10
作者
Busi, F [1 ]
Cresteil, T [1 ]
机构
[1] ICSN, CNRS, UPR2301, F-91198 Gif Sur Yvette, France
关键词
alternative splicing; CYP3A5; genotype; melting curve; phenotype; quantitative real-time PCR;
D O I
10.1097/01213011-200506000-00010
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Alternative splicing is required to increase the mRNA diversity of many genes, but can also be responsible for the abnormal expression of genes. For example, the CYP3A5*3 defective allele is caused by a single nucleotide polymorphism in intron 3. This mutation activates a cryptic acceptor splice site, which leads to the insertion of an intronic sequence containing premature termination codons in the mature mRNA, and hence the very low CYP3A5 protein expression in 75% of the Caucasian population. In the present study, we propose a novel strategy based on the quantitative real-time polymerase chain reaction with SYBR Green I chemistry, followed by melting curve analysis, to demonstrate and quantify the amount of splice variant mRNA. Using oligonucleotides flanking the insertion site, two products with different size can be obtained, which can be resolved by melting curve analysis. The relative ratio of differently spliced RNA can be estimated at the plateau phase by using the peak height ratio. For the CYP3A5 gene, the genotype, the level of expression and the proportion of alternatively spliced products were determined in a single reaction without DNA sequencing. (c) 2005 Lippincott Williams & Wilkins.
引用
收藏
页码:433 / 439
页数:7
相关论文
共 30 条
[1]   Advances in the pharmacogenomics of adverse drug reactions [J].
I Alvarado ;
M-L Wong ;
J Licinio .
The Pharmacogenomics Journal, 2002, 2 (5) :273-273
[2]   Finishing the euchromatic sequence of the human genome [J].
Collins, FS ;
Lander, ES ;
Rogers, J ;
Waterston, RH .
NATURE, 2004, 431 (7011) :931-945
[3]   MULTIPLE SEQUENCE ALIGNMENT WITH HIERARCHICAL-CLUSTERING [J].
CORPET, F .
NUCLEIC ACIDS RESEARCH, 1988, 16 (22) :10881-10890
[4]   Moving towards individualized medicine with pharmacogenomics [J].
Evans, WE ;
Relling, MV .
NATURE, 2004, 429 (6990) :464-468
[5]   The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons [J].
Finta, C ;
Zaphiropoulos, PG .
GENE, 2000, 260 (1-2) :13-23
[6]   CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation [J].
Goto, M ;
Masuda, S ;
Kiuchi, T ;
Ogura, Y ;
Oike, F ;
Okuda, M ;
Tanaka, K ;
Inui, K .
PHARMACOGENETICS, 2004, 14 (07) :471-478
[7]   Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping [J].
Goyenvalle, A ;
Vulin, A ;
Fougerousse, F ;
Leturcq, F ;
Kaplan, JC ;
Garcia, L ;
Danos, O .
SCIENCE, 2004, 306 (5702) :1796-1799
[8]   The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients [J].
Haufroid, V ;
Mourad, M ;
Van Kerckhove, V ;
Wawrzyniak, J ;
De Meyer, M ;
Eddour, DC ;
Malaise, J ;
Lison, D ;
Squifflet, JP ;
Wallemacq, P .
PHARMACOGENETICS, 2004, 14 (03) :147-154
[9]   Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus [J].
Hesselink, DA ;
van Schaik, RHN ;
van der Heiden, IP ;
van der Werf, M ;
Gregoor, PJHS ;
Lindemans, J ;
Weimar, W ;
van Gelder, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (03) :245-254
[10]   Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression [J].
Kuehl, P ;
Zhang, J ;
Lin, Y ;
Lamba, J ;
Assem, M ;
Schuetz, J ;
Watkins, PB ;
Daly, A ;
Wrighton, SA ;
Hall, SD ;
Maurel, P ;
Relling, M ;
Brimer, C ;
Yasuda, K ;
Venkataramanan, R ;
Strom, S ;
Thummel, K ;
Boguski, MS ;
Schuetz, E .
NATURE GENETICS, 2001, 27 (04) :383-391